Algorithm for the management of CAPS during pregnancy (modified from Lim et al⁴⁵ ). ∗Expert opinion suggests eculizumab in cases with prominent thrombotic microangiopathic features, and rituximab in cases with worsening thrombocytopenia without documented thrombosis as the most prominent clinical concern.